TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
TG THERAP (NASDAQ: TGTX) Delayed: 49.52 +1.47 (3.06%)
Previous Close $48.05    52 Week High $14.87 
Open $48.05    52 Week Low $4.90 
Day High $50.41    P/E N/A 
Day Low $47.96    EPS $-0.67 
Volume 2,548,896